Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 452.46 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Y-mAbs Therapeutics, Inc. - Special Call Transcript

Oct 06, 2020 / 01:00PM GMT
Release Date Price: $38.13 (-8.56%)
Operator

Greetings, and welcome to the Y-mAbs Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host for today's conference, Dr. Claus Møller. Thank you, Doctor. Please go ahead.

Claus Juan MÃ;ller San Pedro
Y-mAbs Therapeutics, Inc. - CEO & Director

¸ -

Thank you very much. Good morning, everybody, and thanks for joining us today. I'm joined today by Y-mAbs Founder, Chairman and President, Thomas Gad; and our Chief Financial Officer, Bo Kruse. We are holding this call to provide an update of securing regulatory status for omburtamab. We completed the rolling submission for the BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in August this year. And late on Friday, October 2, we received refusal -- a refusal to file a letter from the FDA.

Upon its preliminary review, the FDA determined that certain parts of the CMC module and the clinical module of the BLA required further detail to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot